Visit https://www.peervoice.com/SCY860 to view the entire programme with slides. After completing “Practice Essentials for Improving Outcomes in Waldenstrom Macroglobulinemia”, participants will be able to: Evaluate the current long-term data and relevant trials for BTK inhibitors in the treatment of first-line and relapsed/refractory Waldenström macroglobulinemia (WM); Formulate an appropriate treatment plan based on the current data to optimize long-term outcomes for patients with WM.